Why the study?
Recent studies demonstrated the efficacy of EV-ICDs in a large global population, but experience in patients with genetic heart diseases was not reported.
Observational
No
Answers are grounded in this paper and cite their sources.
Early single-center experience supports EV-ICD feasibility in GHD patients including athletes; leaves open need for larger prospective trials before practice change.
The extravascular implantable cardioverter-defibrillator (EV-ICD) was designed to avoid lead-related complications associated with transvenous ICD (TV-ICD) systems, deliver antitachycardia pacing (ATP) to mitigate ICD shock, and reduce generator size to provide an advantage over a subcutaneous ICD (S-ICD).1,2 Recent studies demonstrated the efficacy of EV-ICDs in a large global population, but the experience in patients with genetic heart diseases (GHDs) was not reported.3,4 Therefore, we sought to examine the experience of patients with GHDs who received an EV-ICD at Mayo Clinic.
No takes yet. Share an insight, caveat, or question.
Coderre et al. (2025) conducted an observational in Genetic heart disease. Extravascular implantable cardioverter-defibrillator (EV-ICD) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: